View Older Stories View More Recent Stories
-
Abbott Labs (ABT) PT Lowered to $125 at RBC Capital
-
Intra-Cellular Therapies (ITCI) Prices Public Offering of Common Stock
-
Intra-Cellular Therapies Prices Public Offering of Common Stock
-
Royal Bank of Canada announces NVCC AT1 Limited Recourse Capital Notes issue
-
Clearwater Analytics to Participate in Upcoming Investor Conferences in Second Quarter 2024
-
RBC Capital Reiterates Outperform Rating on Bank of America (BAC)
-
RBC Capital Cautious on ProLogis (PLD): 'customers remain focused on controlling costs'
-
RBC Capital Issues Negative Sentiment on Sage Therapeutics (SAGE), 'we are not altogether surprised by the stock move'
-
Ashtead Group Plc (AHT:LN) (ASHTY) PT Raised to GBP53 at RBC Capital
-
RBC Capital Upgrades Pennon Group Plc. (PNN:LN) (PEGRF) to Outperform
-
Abbott's device sales drive profit beat, but shares fall as forecast disappoints
-
UnitedHealth Group (UNH) PT Lowered to $555 at RBC Capital
-
Nuvation Bio Inc (NUVB) PT Raised to $5 at RBC Capital
-
Johnson & Johnson (JNJ) PT Lowered to $175 at RBC Capital
-
APi Group Corporation (APG) Prices 11M Share Offering at $37.50/sh
-
APi Group Announces Pricing of Public Offering of Common Stock
-
Analysis-Indonesia's plunging rupiah twists the policy plot
-
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Intra-Cellular Therapies (ITCI) Announces Proposed $500M Share Offering
-
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
-
RBC Capital Markets launches RBC Clear™, a Cash Management solution that will focus on Fortune 1000 corporations in the United States
-
RBC Capital Upgrades Admiral Group Plc. (ADM:LN) (AMIGY) to Outperform
-
Ducommun (DCO) Rejects Unsolicited, Non-Binding Indication of Interest From Albion River
-
Ducommun Incorporated Rejects Unsolicited, Non-Binding Indication of Interest From Albion River
-
Goldman Sachs (GS) PT Raised to $405 at RBC Capital
-
Boeing (BA) PT Lowered to $215 at RBC Capital
-
China's cycle of dollar hoarding and weakening yuan gets vicious
-
Instant view: China's Q1 GDP grows 5.3% y/y, well above forecast
-
Instant view: China's Q1 GDP grows 5.3% y/y, well above forecast
-
Instant view: China's Q1 GDP grows 5.3% y/y, well above forecast
-
China's 1st quarter growth solid but March data shows demand still feeble
-
PACS Group, Inc. Announces Closing of Its Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares from the Selling Stockholders
-
MFA Financial (MFA) Prices $75M Notes Offering
-
MFA Financial, Inc. Announces Pricing of Public Offering of Senior Notes
-
Form MA/A RBC Capital Markets,
-
Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer
-
4D Molecular Therapeutics (FDMT) PT Raised to $40 at RBC Capital
-
Hilton Foods Group Plc. (HFG:LN) PT Raised to GBP10 at RBC Capital
-
RBC Capital Starts Saipem (SPM:IM) (SAPMF) at Outperform, 'strong backlog underpinning a higher revenue and margin outlook'
-
7 things you must know about this market
-
Surging US energy shares reflect robust growth, inflation worries
-
RBC Capital Upgrades Taylor Wimpey Plc. (TW/:LN) (TWODF) to Outperform
-
RBC Capital Downgrades Berkeley Group Holdings Plc. (BKG:LN) (BKGFF) to Underperform
-
Zalando SE (ZAL:GR) (ZLNDY) PT Raised to EUR40 at RBC Capital
-
salesforce.com (CRM) PT Raised to $350 at RBC Capital
-
Constellation Brands (STZ) PT Raised to $308 at RBC Capital
-
CarMax (KMX) PT Lowered to $73 at RBC Capital
-
Nurix Therapeutics (NRIX) Prices Upsized 10.17M Share Offering at $15/sh
-
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
-
Nurix Therapeutics (NRIX) Announces Proposed $125M Share Offering

